v3.26.1
Segment Information (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Segment Reporting Information [Line Items]              
Operating expenses $ 6,874   $ 7,462   $ 13,821 $ 14,020  
Segment net loss 6,370 $ 6,780 7,144 $ 6,302 13,150 13,446  
Total Assets 41,639       41,639   $ 39,393
Biopharm Division [Member]              
Segment Reporting Information [Line Items]              
Operating expenses 6,200       12,200    
Segment net loss 6,154   6,366   12,210 12,011  
Total Assets 41,100       41,100    
Neurostimulation Division [Member]              
Segment Reporting Information [Line Items]              
Operating expenses 200       900    
Segment net loss 216   $ 778   940 $ 1,435  
Total Assets $ 500       $ 500